Form 4: Teva Pharmaceutical Executive Sells Shares to Cover Tax Obligations After Vesting
SEC Form 4 Filing
Christine Fox, EVP at Teva Pharmaceutical Industries, sold 19,388 ordinary shares to cover tax obligations after 63,492 restricted share units vested.
Summary
- Christine Fox, an Executive Vice President at Teva Pharmaceutical Industries, sold 19,388 ordinary shares on November 20, 2024, at a price of $16.8705 per share.
- This sale was to cover tax withholding obligations related to the vesting of 63,492 restricted share units.
- The restricted share units were granted on November 20, 2023, and vested on November 20, 2024.
- The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2024.
- Following the transaction, Ms. Fox directly owns 44,104 ordinary shares.
Sentiment
Score: 5
Explanation: This is a routine transaction related to executive compensation and does not indicate any positive or negative sentiment about the company's performance.
Industry Context
This is a routine transaction for executives who receive stock-based compensation. The use of a 10b5-1 plan indicates the sale was pre-planned and not based on any new material non-public information.
Comparison to Industry Standards
- The use of Rule 10b5-1 trading plans is a common practice among executives at publicly traded companies, including pharmaceutical firms like Pfizer, AbbVie, and Johnson & Johnson, to manage their stock sales and avoid accusations of insider trading.
- The vesting schedule of restricted share units, with a portion vesting annually over several years, is also a standard practice in executive compensation packages across the industry.
- The tax withholding obligations and subsequent share sales are typical for executives receiving equity compensation.
Stakeholder Impact
- The sale of shares by an executive may have a minor impact on the stock price, but it is unlikely to be significant given the pre-planned nature of the transaction.
Key Dates
| Date | Description |
|---|---|
| 2023-11-20 | Restricted share units were granted. |
| 2024-08-13 | Rule 10b5-1 trading plan adopted. |
| 2024-11-20 | Restricted share units vested and shares were sold. |
| 2024-11-21 | Form 4 filing date. |
Keywords
Teva Pharmaceutical Industries, insider trading, Form 4, restricted share units, Rule 10b5-1, executive compensation, share sale, Christine Fox
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.